12:00 AM
 | 
Sep 06, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Procoralan ivabradine: Phase III data

In the double-blind, international Phase III SHIFT trial in 6,558 patients with moderate to severe CHF, poor left-ventricular ejection function and a heart rate >=70 bpm, Procoralan met the composite primary endpoint of significantly reducing the incidence of CV death or hospital admission for worsening heart failure vs. placebo at a median follow-up...

Read the full 242 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >